PR Newswire: news distribution, targeting and monitoring
2014

Zacks Bull and Bear of the Day Highlights: Winnebago Industries, Gold Fields, Teva Pharmaceutical Industries, Biogen and Novartis

Share with Twitter Share with LinkedIn

CHICAGO, March 11, 2013 /PRNewswire/ -- Zacks Equity Research highlights Winnebago Industries, Inc. (NYSE: WGO) as the Bull of the Day and Gold Fields Limited (NYSE: GFI) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Biogen (Nasdaq: BIIB) and Novartis (NYSE: NVS).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.

Here is a synopsis of all five stocks:

Bull of the Day:

How can you tell the economy is back? Because consumers are buying RVs again. Winnebago Industries, Inc. (NYSE: WGO) managed to make it through the Great Recession, gobbling up market share along the way. This Zacks Rank #1 (Strong Buy) is now poised for triple digit earnings growth in 2013 as RV sales rebound.

Winnebago's brand recognition is so strong that when you think of RVs it's the first name that comes to mind. Founded in 1958 in Iowa, Winnebago manufactures a variety of recreation vehicles ("RVs") including motor homes, travel trailers and fifth wheel products.

Given consolidation in the industry during the Great Recession, Winnebago was able to add to its market share and now has about 20% of the RV market.

Motor home sales peaked in 2004 at 69,000 and plunged during the Great Recession. By 2011, only 25,000 motor homes were shipped. But that number is expected to slowly rise as the economy improves and the Baby Boomers age.

Bear of the Day:

It's tough being a gold miner in 2013. Gold prices have slid to 8 month lows. Many miners are also having trouble getting the yellow metal out of the ground. Gold Fields Limited (NYSE: GFI) , a South African miner, recently provided disappointing 2013 production guidance which sent earnings estimates tumbling. It's a Zacks Rank #5 (Strong Sell).

Gold Fields is an unhedged gold producer with 6 operating mines in Australia, Ghana, Peru and South Africa. Four other projects are ongoing.

Even if gold prices are elevated, a gold miner doesn't make money without getting it out of the ground. A whole host of things can impact production from natural disasters to geopolitical risks to power outages due to poor infrastructure.

In the fourth quarter of 2012, Gold Fields suffered from major strikes. Gold production fell 7% in the quarter due to the strikes.

Latest Posts on the Zacks Analyst Blog:

Teva Enrolls Patients in MS Study

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech recently announced that the first patient for their phase III CONCERTO study has been enrolled.

The multinational, randomized, double-blind placebo-controlled study is being conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Two doses of laquinimod (0.6 mg and 1.2 mg) will be evaluated in the study with the primary endpoint being confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS).

Laquinimod has been evaluated in two other phase III trials (ALLEGRO and BRAVO) earlier. The candidate is also being studied for Crohn's disease and lupus.

The successful development and launch of laquinimod would help strengthen Teva's multiple sclerosis drug portfolio. Being an oral formulation, laquinimod could provide an advantage over therapies that require injection or infusion.

Teva already has a multiple sclerosis product in its portfolio – Copaxone. Copaxone is approved for the reduction of the frequency of relapses in RRMS, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

We are pleased with Teva's efforts to expand its multiple sclerosis franchise. The multiple sclerosis market represents significant commercial potential. The disease is estimated to affect more than 400,000 people in the US . Worldwide, it is estimated that more than two million people may be suffering from multiple sclerosis.

Key players in the multiple sclerosis market include Biogen (Nasdaq: BIIB) and Novartis (NYSE: NVS) among others.

Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.



RELATED LINKS
http://www.zacks.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release